The dose of aspirin for the prevention of cardiovascular and cerebrovascular events

References

• Dreser H. Pharmakologisches über aspirin (acetylsalicylsäure). Pfluger’s Arch 1899;76:306–18
   Google Scholar
• Craven LL. Experiences with aspirin (acetylsalicylic acid) in the non-specific prophylaxis of coronary thrombosis. Mississippi Valley Med J 1953;75:38–44
   PubMedGoogle Scholar
• Smith S, Blair S, Bonow R, et al. AHA/ACC guidelines for preventing heart attack and death in patients with athero-sclerotic cardiovascular disease: 2001 update. Circulation 2001;104:1577–9
   PubMed Web of Science ®Google Scholar
• Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention [The American Academy of Neurology affirms the value of this guideline]. Stroke 2006;37:577–617
   PubMed Web of Science ®Google Scholar
• Awtry E, Loscalzo J. Aspirin. Circulation 2000;101:1206–18
   PubMed Web of Science ®Google Scholar
• Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. New Engl J Med 2005;353:2373–83
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135–43
   PubMed Web of Science ®Google Scholar
• Ikonomidis I, Andreotti F, Economou E, et al. Increased pro-inflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100:793–8
   PubMed Web of Science ®Google Scholar
• Ikonomidis I, Andreotti F, Nihoyannopoulos P. Reduction of daily life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage stimulating factor. Heart 2004;90: 389–93
   Google Scholar
• Ikonomidis I, Lekakis J, Vamvakou G, et al. Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. Am Heart J 2005;149:832–9
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl J Med 1997;336:973–9
   PubMed Web of Science ®Google Scholar
• Steer KA, Wallace TM, Bolton CH, et al. Aspirin protects low density lipoprotein from oxidative modification. Heart 1997;77:333–7
   PubMed Web of Science ®Google Scholar
• Geppert A, Graf S, Beckmann R, et al. Concentration of endogenous tPA antigen in coronary artery disease relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease. Arterioscler Thromb Vasc Biol 1998;18:1634–42
   PubMed Web of Science ®Google Scholar
• Chiang N, Burmudez EA, Ridker PM, et al. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci USA 2004;101:15178–83
   PubMed Web of Science ®Google Scholar
• Andersen K, Hurlen M, Arnesen H, et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002;108:37–42
   PubMed Web of Science ®Google Scholar
• Wang JC, Aucoin-Barry D, Manuelian D, et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003;92:1492–4
   PubMed Web of Science ®Google Scholar
• Chen W-H, Lee P-Y, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122–6
   Google Scholar
• Helgason CM, Tortorice KL, Winkler SR, et al. Aspirin response and failure in cerebral infarction. Stroke 1993;24:345–50
   PubMed Web of Science ®Google Scholar
• Syrbe G, Redlich H, Weidlich B, et al. Individual dosing of ASA prophylaxis by controlling platelet aggregation. Clin Appl Thrombosis/Hemostasis 2001;7:209–13
   PubMed Web of Science ®Google Scholar
• Schwartz KA, Schwartz DE, Pittsley RA, et al. A new method for measuring inhibition of platelet function by nonsteroidal anti-inflammatory drugs. J Lab Clin Med 2002;139:227–33
   PubMedGoogle Scholar
• Alberts MJ, Bergman D, Molner E, et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004;35:175–8
   PubMed Web of Science ®Google Scholar
• Lee PY, Chen WH, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005;118:723–7
   PubMed Web of Science ®Google Scholar
• Hung J, Lam J, Lacoste L, et al. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995;92:2432–6
   PubMed Web of Science ®Google Scholar
• Kalliakmanis A, Harisi M, Manolis E, et al. The acute effect of smoking a cigarette in ex vivo ADP platelet aggregation in habitual smokers. Haema 2000;3:229–232
   Google Scholar
• Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. New Engl J Med 2005;352:1293–304
   PubMed Web of Science ®Google Scholar
• Sacco M, Pellegrini F, Roncaglioni M, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetics patients. Diabetes Care 2003;26:3264–72
   PubMed Web of Science ®Google Scholar
• Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin) – its relation to metabolic control. Thromb Res 2004;113:101–13
   PubMed Web of Science ®Google Scholar
• Abaci A, Yilmaz Y, Caliskan M, et al. Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes. Thromb Res 2005;116:465–70
   PubMed Web of Science ®Google Scholar
• Tamminen M, Lassial R, Westerbacka J, et al. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects.Int J Obes 2003;27:907–11
   PubMed Web of Science ®Google Scholar
• Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005;46:1705–9
   Google Scholar
• Schwartz KA, Schwartz DE, Ghosheh K, et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005;95:973–5
   PubMed Web of Science ®Google Scholar
• Macchi L, Christiaens L, Brabant S, et al. Resistance in vitro to low-dose aspirin is associated with platelet P1a1 (GP IIIa) polymorphism but not with C807T (GP Ia/IIa) and C-5T Kozak (GP Ib alpha) polymorphisms. J Am Coll Cardiol 2003;42:1115–9
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. New Engl J Med 2001;345:1809–17
   Google Scholar
• The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor stroke. New Engl J Med 1991;325:1261–6
   PubMed Web of Science ®Google Scholar
• UK TIA Study Group. United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044–54
   PubMed Web of Science ®Google Scholar
• Taylor D, Barnet H, Haynes R, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomized controlled trial. Lancet 1999;353:2179–84
   PubMed Web of Science ®Google Scholar
• Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. New Engl J Med 2003;348:891–9
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71–86 [erratum in: Br Med J 2002;324: 141]
   Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al.; for the Clopidogrel in Unstable Angina to Prevent Recurrent Events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001;345:494–502 [erratum in: New Engl J Med 2001;345:1716; New Engl J Med 2001;345: 1506)
   Google Scholar
• Peters R, Mehta S, Fox K, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes. Circulation 2003;108:1682–7
   PubMed Web of Science ®Google Scholar
• Topol EJ, Easton D, Harrington R, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003;108:399–406
   PubMed Web of Science ®Google Scholar
• Aronow HD, Califf RM, Harrington RA, et al. Higher dose aspirin is associated with reduced mortality and more serious bleeding in patients with recent cerebrovascular or coronary ischemic events: insights from the BRAVO trial. American Heart Association Scientific Sessions [abstract November 12, 2003]
   Google Scholar
• Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin:meta-analysis. Br Med J 2000;321:1183–7
   PubMed Web of Science ®Google Scholar
• Serebruany V, Malinin A, Eisert R, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192 036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005;95:1218–22
   PubMed Web of Science ®Google Scholar
• Laine L, McQuaid K. Meta-analysis of bleeding with low-dose aspirin and clopidogrel in randomized controlled trials [DDW 2006 abstract; in press]
   Google Scholar
• Laine L, McQuaid K. Bleeding complications related to aspirin dose. Am J Cardiol 2005;96:1035–6
   PubMed Web of Science ®Google Scholar
• Fisher M, Knappertz V. Comments in response to ‘Analysis of risk of bleeding complications after different doses of aspirin in 192 036 patients enrolled in 31 randomized controlled trials’. Am J Cardiol 2005;96:1467
   PubMed Web of Science ®Google Scholar
• Harrison MJG, Marshall J, Meadows JC, et al. Effect of aspirin in amaurosis fugax. Lancet 1971;2:734–44
   Google Scholar
• Weiss HJ, Aledort LM. Impaired platelet–connective-tissue reaction in man after aspirin ingestion. Lancet 1967;2:495–7
   PubMed Web of Science ®Google Scholar
• Dyken ML, Barnett HJM, Easton D, et al. Low-dose aspirin and stroke: ‘It ain’t necessarily so’. Stroke 1992;23:1395–9
   PubMed Web of Science ®Google Scholar
• Patrono C, Roth GJ. Aspirin in ischemic cerebrovascular disease: how strong is the case for a different dosing regimen? Stroke 1996;27:756–60
   PubMed Web of Science ®Google Scholar
• Barnett HJM, Kaste M, Meldrum H, et al. Aspirin dose in stroke prevention beautiful hypotheses slain by ugly facts. Stroke 1996;27:588–92
   PubMed Web of Science ®Google Scholar
• Hart RG, Harrison MJ. Aspirin wars: the optimal dose of aspirin to prevent stroke. Stroke 1996;27:585–7
   PubMed Web of Science ®Google Scholar
• Johnson ES, Lanes SF, Wentworth 3rd CE, et al. A meta-regression analysis of the dose–response effect of aspirin on stroke. Arch Intern Med 1999;159:1248–53
   PubMed Web of Science ®Google Scholar
• Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. New Engl J Med 1978;299:53–9
   PubMed Web of Science ®Google Scholar
• Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomized controlled trials. Br J Clin Pharmacol 1993;35:219–26
   Google Scholar
• Gorelick P, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. J Am Med Assoc 2003;289:2947–57
   PubMed Web of Science ®Google Scholar
• Chimowitz M, Lynn M, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. New Engl J Med 2005;352:1305–16
   Google Scholar